Mergers and Acquisitions

The acquisition would combine Sangamo’s ex vivo gene-editing capabilities with TxCell's regulatory T-cell (Treg) expertise to create chimeric antigen receptor (CAR)-Treg therapies.

Otsuka Pharmaceutical will acquire Visterra, a clinical-stage biotechnology company focused on developing antibody-based therapies, for approximately $430 million.

The company has received clearance from the United States Federal Trade Commission for the proposed acquisition of Shire, a deal valued at $62 billion.

Amazon will acquire PillPack, an online pharmacy that offers pre-sorted doses of medications and home delivery.

Sanofi will sell Zentiva, its European generics business, to private equity investor Advent International.

The acquisition is expected to strengthen Sanofi’s R&D strategy with Ablynx’s nanobody technology platform.

The acquisition is expected to strengthen Roche’s personalized healthcare strategy.

Bayer completed its acquisition of Monsanto, the largest in Bayer’s history.

Agilent Technologies expects the acquisition to improve its current software portfolio.

Bayer received conditional approval from the Antitrust Division of the United States Department of Justice to acquire Monsanto in a deal worth $66 billion.

The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.

The acquisition is expected to strengthen Novartis’ gene therapy pipeline.

Eli Lilly will acquire ARMO BioSciences to strengthen Lilly's immuno-oncology program.

Johnson & Johnson’s Janssen Biotech will acquire biotechnology company BeneVir Biopharm to strengthen Janssen’s immunotherapy platform.

Takeda expands its global and therapy base with announced acquisition of Shire.

Fresenius Kabi claims that Akorn failed to fulfill several closing conditions.

Global investment firm Advent to acquire and invest in Sanofi’s European generics business, Zentiva, to boost its position in European market.

The transaction is part of Merck KGaA’s strategy to actively shape its product portfolio and focus on innovation-driven business.

According to Alexion, the acquisition will help rebuild its clinical pipeline.

The acquisition is expected to accelerate progress towards personalized cancer healthcare.

Roche has acquired a program to develop regenerative therapies for multiple sclerosis.

Fujifilm acquires cell culture media companies Irvine Scientific Sales Company and IS Japan.

The acquisition strengthens Celgene’s position in the global cellular immunotherapy space.

Takeda is considering approaching Shire with a possible offer.

Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.